Ryosuke Ushijima
Merck & Co.
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Ryosuke Ushijima.
Tetrahedron | 1998
Norikazu Ohtake; Yasuyuki Imai; Ryosuke Ushijima
Abstract The BO-2502A side chain intermediate 3 was prepared via the diastereoselective lactamization of the in situ prepared amino diacid anhydride 14 as a key step. The diastereoselectivity of this step was found to be 53:1 (96% de).
Tetrahedron-asymmetry | 1997
Norikazu Ohtake; Hideki Jona; Shigemitsu Okada; Osamu Okamoto; Yasuyuki Imai; Ryosuke Ushijima; Susumu Nakagawa
Abstract The key intermediate of the BO-2727 side chain 3 was prepared diastereoselectively by two alternative methods: via the aldol reaction of (2S,4R)-N-Boc- tert -butyldimethylsilyloxyprolinal 5 with in-situ -generated ketene acetal 9 in the presence of TiCl 4 (95% de) and via the catalytic hydrogenation of β-keto amide 6i using (S)-BINAP-Ru as a catalyst (98% de).
Tetrahedron Letters | 1997
Joseph D. Armstrong; Jennifer L. Keller; Joseph J. Lynch; T. Liu; Frederick W. Hartner; Norikazu Ohtake; Shigemitsu Okada; Yasuyuki Imai; Osamu Okamoto; Ryosuke Ushijima; Susumu Nakagawa; Ralph P. Volante
Abstract An efficient asymmetric synthesis of the mercaptopyrrolidine side chain 2 1s described. The β-ketoester 4 is hydrogenated diastereoselectively to give the (R)-β-hydroxyester 5. The remaining functional groups are installed via a thiol Mitsunobu reaction and a reduction of a secondary amide to produce 2 in 34% overall yield from BOC-L-trans-4-hydroxyproline methylester 3 (Scheme 1).
Bioorganic & Medicinal Chemistry Letters | 1997
Norikazu Ohtake; Hideaki Imamura; Hideo Kiyonaga; Hideki Jona; Masayuki Ogawa; Shigemitsu Okada; Aya Shimizu; Minoru Moriya; Hiroki Sato; Yushin Tominaga; Koji Yamada; Masato Nakano; Ryosuke Ushijima; Susumu Nakagawa
Abstract A new series of carbapenems, in which disubstituted-aminothiocarbonylthio moiety, directly attached to the C-2 position, were prepared and evaluated for their antibacterial potency. These analogs showed potent activity against high-level MRSA. Among them, 9e and 9i were found to exhibit good in vivo efficacy comparable to that of vancomycin, for mouse septicemia model with high-level MRSA.
Archive | 1988
Susumu Nakagawa; Norikazu Otake; Ryosuke Ushijima
Bioorganic & Medicinal Chemistry | 1998
Norikazu Ohtake; Hideaki Imamura; Hideki Jona; Hideo Kiyonaga; Aya Shimizu; Minoru Moriya; Hiroki Sato; Masato Nakano; Ryosuke Ushijima; Susumu Nakagawa
Bioorganic & Medicinal Chemistry Letters | 2000
Hideaki Imamura; Norikazu Ohtake; Aya Shimizu; Hideki Jona; Hiroki Sato; Rie Nagano; Ryosuke Ushijima; Koji Yamada; Terutaka Hashizume; Hajime Morishima
Archive | 1985
Susumu Nakagawa; Ryosuke Ushijima; Eiichi Mano; Norikazu Ban; Minoru Sanada
Archive | 1983
Susumu Nakagawa; Fumio Nakano; Ryosuke Ushijima; Ikuo Iwatsuki; Shuichi Iwadare
Archive | 1990
Susumu Nakagawa; Koji Yamada; Ryosuke Ushijima